Top

Published in:

01-06-2015 | Review

Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective

Authors: Angel Lanas, Carla J. Gargallo

Published in: Journal of Gastroenterology | Issue 6/2015

Abstract

Low-dose aspirin, alone or combined with other antiplatelet agents, is increasingly prescribed for cardiovascular prevention. However, the cardiovascular benefits should be evaluated together with the gastrointestinal risks. Low-dose aspirin is associated with upper and lower gastrointestinal injury, although lower gastrointestinal effects are poorly characterized. This gastrointestinal risk differs among antiplatelets drugs users. The most important risk factors are history of peptic ulcer, older age, and concomitant use of non-steroidal anti-inflammatory drugs or dual antiplatelet therapy. Effective upper gastrointestinal prevention strategies are available and should be used in at-risk patients taking low-dose aspirin or clopidogrel. Proton pump inhibitors seem to be the best gastroprotective agents, whereas the benefits of Helicobacter pylori eradication are still unclear. Low-dose aspirin has additional effects in the gastrointestinal tract. A large body of evidence indicates that it can protect against different cancers, in particular colorectal cancer. This effect could modify the future indications for use of low-dose aspirin and the risk–benefit balance.

Casado-Arroyo R, Bayrak F, Sarkozy A, et al. Role of ASA in the primary and secondary prevention of cardiovascular events. Best Pract Res Clin Gastroenterol. 2012;26(2):113–23.PubMedCrossRef

Calonge N, Petitti DB, DeWitt TG, et al. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150:396–404.CrossRef

Casado-Arroyo R, Gargallo C, LanasArbeloa A. Balancing the risk and benefits of low-dose aspirin in clinical practice. Best Pract Res Clin Gastroenterol. 2012;26(2):173–84.PubMedCrossRef

Baigent C, Blackwell L, Collins R, et al. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849.PubMedCrossRef

Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther. 2005;22(9):795–801.PubMedCrossRef

Cayla G, Collet JP, Silvain J, et al. Prevalence and clinical impact of upper gastrointestinal symptoms in subjects treated with low-dose aspirin: the UGLA survey. Int J Cardiol. 2012;156(1):69–75.PubMedCrossRef

Biondi-Zoccai GG, Lotrionte M, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006;27:2667–74.PubMedCrossRef

Cea Soriano L, Hill C, Johansson S. Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study. Neurology. 2011;76(8):740–6.PubMedCrossRef

Rodríguez LA, Cea-Soriano L, Martín-Merino E, Johansson S. Discontinuation of low-dose aspirin and risk of myocardial infarction: case-control study in UK primary care. BMJ. 2011;19(343):d4094.CrossRef

10.

Muller P, Fuchs W, Simon B. Studies on protective effect of lansoprazole on human gastric mucosa against low-dose acetylsalicylic. An endoscopic controlled double-blind study. Arzneimittelforshung. 1997;47:758–60.

11.

Moore A, Bjarnason I, Cryer B, et al. Evidence for endoscopic ulcers as meaningful surrogate endpoint for clinically significant upper gastrointestinal harm. Clin Gastroenterol Hepatol. 2009;7(11):1156–63.PubMedCrossRef

12.

Laine L, Maller ES, Yu C, et al. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology. 2004;127(2):395–402.PubMedCrossRef

13.

Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology. 1999;117(1):17–25.PubMedCrossRef

14.

Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995;310:827–30.PubMedCentralPubMedCrossRef

15.

Bhatt DL, Scheiman J, Abraham NS, American College of Cardiology Foundation, American College of Gastroenterology, American Heart Association, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2008;103(11):2890–907.PubMedCrossRef

16.

Hernández-Díaz S, García Rodríguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med. 2006;4:22.PubMedCentralPubMedCrossRef

17.

Lanas A, Wu P, Medin J, Mills EJ. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clin Gastroenterol Hepatol. 2011;9(9):762–768.e6.PubMedCrossRef

18.

Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet. 2002;359(9300):9–13.PubMedCrossRef

19.

García Rodríguez LA, Hernández-Díaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol. 2001;52(5):563–71.PubMedCrossRef

20.

Lanas A, García-Rodríguez LA, Arroyo MT, Asociación Española de Gastroenterología, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006;55(12):1731–8.PubMedCentralPubMedCrossRef

21.

Taha AS, Angerson WJ, Prasad R, et al. Clinical trial: the incidence and early mortality after peptic ulcer perforation, and the use of low-dose aspirin and nonsteroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2008;28(7):878–85.PubMed

22.

Lanas A, Serrano P, Bajador E, et al. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology. 1997;112:683–9.PubMedCrossRef

23.

Lanas A, Perez-Aisa MA, Feu F, et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol. 2005;100(8):1685–93.PubMedCrossRef

24.

Moore RA, Derry S, McQuay HJ. Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes. Arthritis Res Ther. 2008;10(1):R7.0 (1685–93).

25.

Smecuol E, et al. Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin Gastroenterol Hepatol. 2009;2009(7):524–9.CrossRef

26.

Strate LL, Liu YL, Huang ES, et al. Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding. Gastroenterology. 2011;140(5):1427–33.PubMedCentralPubMedCrossRef

27.

Nagata N, Niikura R, Aoki T, et al. Colonic diverticular hemorrhage associated with the use of nonsteroidal anti-inflammatory drugs, low-dose aspirin, antiplatelet drugs, and dual therapy. J Gastroenterol Hepatol. 2014;29(10):1786–93.PubMedCrossRef

28.

Lanas A, Carrera P, Arguedas Y, et al. Risk of upper and lower gastrointestinal bleeding in patients taking non-steroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol. 2014. doi:10.1016/j.cgh.2014.11.007.

29.

Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. New Engl J Med. 2003;348(10):883–90.PubMedCrossRef

30.

Logan RFA, Grainge MJ, Shepherd VC, et al. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology. 2008;134(1):29–38.PubMedCrossRef

31.

Benamouzig R, Deyra J, Martin A, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology. 2003;125(2):328–36.PubMedCrossRef

32.

Cole BF, Logan RF, Halabi S, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 2009;101(4):256–66.PubMedCrossRef

33.

Flossmann E, Rothwell PM, British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369(9573):1603–13.PubMedCrossRef

34.

Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13(5):518–27.PubMedCrossRef

35.

Chan AT, Giovannucci EL, Meyerhardt JA, et al. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology. 2008;134(1):21–8.PubMedCentralPubMedCrossRef

36.

Chan AT, Giovannucci EL, Meyerhardt JA, et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA. 2005;294(8):914–23.PubMedCentralPubMedCrossRef

37.

Jacobs EJ, Thun MJ, Bain EB, et al. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst. 2007;99(8):608–15.PubMedCrossRef

38.

Chan AT, Manson JE, Feskanich D, et al. Long-term aspirin use and mortality in women. Arch Intern Med. 2007;167(6):562–72.PubMedCrossRef

39.

Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376(9754):1741–50.PubMedCrossRef

40.

Gann PH, Manson JE, Glynn RJ, et al. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst. 1993;85(15):1220–4.PubMedCrossRef

41.

Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA. 2005;294(1):47–55.PubMedCrossRef

42.

Burn J, Bishop DT, Chapman PD, International CAPP Consortium, et al. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila). 2011;4(5):655–65.CrossRef

43.

Ishikawa H, Wakabayashi K, Suzuki S, et al. Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial. Cancer Med. 2013;2(1):50–6.PubMedCentralPubMedCrossRef

44.

Burn J, Bishop DT, Mecklin JP, CAPP2 Investigators, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med. 2008;359(24):2567.PubMedCrossRef

45.

Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302(6):649–58.PubMedCentralPubMedCrossRef

46.

Fork FT, Lafolie P, Tóth E, Lindgärde F. Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers. A gastroscopic study. Scand J Gastroenterol. 2000;35(5):464–9.PubMedCrossRef

47.

Gent M, Beaumont D, Blanchard J, et al. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–39.CrossRef

48.

Tsai TJ, Lai KH, Hsu PI, et al. Upper gastrointestinal lesions in patients receiving clopidogrel anti-platelet therapy. J Formos Med Assoc. 2012;111(12):705–10.PubMedCrossRef

49.

Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med. 2005;352(3):238–44.PubMedCrossRef

50.

Lai KC, Chu KM, Hui WM, et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol. 2006;4(7):860–5 (Epub 2006 Jun 22).PubMedCrossRef

51.

Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008;52:1502–17.PubMedCrossRef

52.

Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012;60(7):645–81.PubMedCrossRef

53.

Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909–17.PubMedCrossRef

54.

Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med. 2000;343:834–9.PubMedCrossRef

55.

Cea Soriano L, Rodriguez LA. Risk of upper gastrointestinal bleeding in a cohort of new users of low-dose ASA for secondary prevention of cardiovascular outcomes. Front Pharmacol. 2010;1:126.PubMedCentralPubMedCrossRef

56.

Lanas A, Fuentes J, Benito R, et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther. 2002;16:779–86.PubMedCrossRef

57.

Ng W, Wong WM, Chen WH, et al. Incidence and predictors of upper gastrointestinal bleeding in patients receiving low-dose aspirin for secondary prevention of cardiovascular events in patients with coronary artery disease. World J Gastroenterol. 2006;12:2923–7.PubMedCentralPubMed

58.

Okada K, Inamori M, Imajo K, et al. Clinical study of upper gastrointestinal bleeding associated with low-dose aspirin in Japanese patients. Hepatogastroenterology. 2009;56:1665–9.PubMed

59.

Serrano P, Lanas A, Arroyo MT, et al. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther. 2002;16:1945–53.PubMedCrossRef

60.

de Abajo FJ, Garcia Rodriguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol. 2001;1:1.PubMedCentralPubMedCrossRef

61.

Sorensen HT, Mellemkjaer L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000;95:2218–24.PubMedCrossRef

62.

Rostom A, Muir K, Dube´ C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol. 2007;5:818–28.PubMedCrossRef

63.

Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA. 2000;284:1247–55.PubMedCrossRef

64.

Schnitzer TJ, Burmester GR, Mysler E, TARGET Study Group, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet. 2004;364(9435):665–74.PubMedCrossRef

65.

Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-1 study. Am J Med. 2006;119:255–66.PubMedCrossRef

66.

Rostom A, Muir K, Dube C, et al. Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of unsaid with gastroprotection and COX-2 inhibitors. Drug Health Patient Safety. 2009;1:1–25.

67.

Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.PubMedCrossRef

68.

Berger PB, Bhatt DL, Fuster V, et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation. 2010;121:2575–83.PubMedCrossRef

69.

[Anonymous]. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council’s General Practice Research Framework. Lancet 1998;351:233–41.

70.

Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347:969–74.PubMedCrossRef

71.

Masclee GM, Valkhoff VE, Coloma PM, et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology. 2014;147(4):784–792.e9 (quiz e13-4).PubMedCrossRef

72.

Fletcher EH, Johnston DE, Fisher CR, et al. Systematic review: Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin. Aliment Pharmacol Ther. 2010;32(7):831–9.PubMedCrossRef

73.

Uemura N, Sugano K, Hiraishi H, MAGICStudy Group, et al. Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: the results from the MAGICstudy. J Gastroenterol. 2014;49(5):814–24.PubMedCentralPubMedCrossRef

74.

Hart J, Hawkey CJ, Lanas A, et al. Predictors of gastroduodenal erosions in patients taking low-dose aspirin. Aliment Pharmacol Ther. 2010;31(1):143–9.PubMedCrossRef

75.

Iijima K, Ara N, Abe Y, et al. Biphasic effects of H. pylori infection on low-dose aspirin-induced gastropathy depending on the gastric acid secretion level. J Gastroenterol. 2012;47(12):1290–7.PubMedCrossRef

76.

Iijima K, Ara N, Abe Y, et al. Gastric acid secretion level modulates the association between Helicobacter pylori infection and low-dose aspirin-induced gastropathy. J Gastroenterol. 2011;46(5):612–9.PubMedCrossRef

77.

Bousser MG, Amarenco P, Chamorro A, PERFORM Study Investigators, et al. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet. 2011;377(9782):2013–22. doi:10.1016/S0140-6736(11)60600-4.PubMedCrossRef

78.

Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353(22):2373–83.PubMedCrossRef

79.

Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000;321:1183–7.PubMedCentralPubMedCrossRef

80.

Uppalapati SS, Boylan JD, Stoltzfus J. Risk factors involved in patients with bleeding peptic ulcers: a case-control study. Dig Dis Sci. 2009;54:593–8.PubMedCrossRef

81.

McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med. 2006;119:624–38.PubMedCrossRef

82.

Graham DY, Smith JL, Spjut HJ, et al. Gastric adaptation. Studies in humans during continuous aspirin administration. Gastroenterology. 1988;95:327.PubMed

83.

Capone ML, Sciulli MG, Tacconelli S, et al. Pharmaco-dynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol. 2005;45:1295–301.PubMedCrossRef

84.

Anzellotti P, Capone ML, Jeyam A, et al. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences. Arthritis Rheum. 2011;63:850–9.PubMedCrossRef

85.

Giral A, Ozdogan O, Celikel CA, et al. Effect of Helicobacter pylori eradication on anti-thrombotic dose aspirin-induced gastroduodenal mucosal injury. Gastroenterol Hepatol. 2004;19(7):773–7.CrossRef

86.

Helicobacter Eradication Aspirin Trial. ClinicalTrials.gov.

87.

Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001;344(13):967–73.PubMedCrossRef

88.

Chan FK, Ching JY, Suen BY, et al. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology. 2013;144(3):528–35.PubMedCrossRef

89.

Donnelly MT, Goddard AF, Filipowicz B, et al. Low-dose misoprostol for the prevention of low-dose aspirin-induced gastroduodenal injury. Aliment Pharmacol Ther. 2000;14(5):529–34.PubMedCrossRef

90.

Goldstein JL, Huang B, Amer F, et al. Ulcer recurrence in high-risk patients receiving nonsteroidal anti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis. Clin Ther. 2004;26(10):1637–43.PubMedCrossRef

91.

Simon B, Elsner H, Muller P. Protective effect of omeprazole against low-dose acetylsalicylic acid. Endoscopic controlled double-blind study in healthy subjects. Arzneimittelforschung. 1995;45(6):701–3.PubMed

92.

Yeomans N, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol. 2008;103(10):2465–73.PubMedCrossRef

93.

Scheiman JM, Devereaux PJ, Herlitz J, et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomized, controlled trial (OBERON). Heart. 2011;97(10):797–802.PubMedCentralPubMedCrossRef

94.

Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346(26):2033–8.PubMedCrossRef

95.

Sugano K, Choi MG, Lin JT, LAVENDER Study Group, et al. Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study. Gut. 2014;63(7):1061–8. doi:10.1136/gutjnl-2013-304722.PubMedCrossRef

96.

Iwakiri R, Higuchi K, Kato M, et al. Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin. Aliment Pharmacol Ther. 2014;40(7):780–95. doi:10.1111/apt.12907.PubMedCrossRef

97.

Taha AS, McCloskey C, Prasad R, et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomized, double-blind, placebo-controlled trial. Lancet. 2009;374(9684):119–25.PubMedCrossRef

98.

Lanas A, García-Rodríguez LA, Arroyo MT, Investigators of the Asociación Española de Gastroenterología (AEG), et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol. 2007;102(3):507–15.PubMedCrossRef

99.

Ng FH, Wong SY, Lam KF, et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology. 2010;138(1):82–8.PubMedCrossRef

100.

Lin KJ, Hernandez-Diaz S, Garcia Rodriguez LA. Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology. 2011;141(1):71–9.PubMedCrossRef

101.

Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2010;152(1):1–9.PubMedCrossRef

102.

Derogar M, Sandblom G, Lundell L, et al. Discontinuation of low-dose aspirin therapy after peptic ulcer bleeding increases risk of death and acute cardiovascular events. Clin Gastroenterol Hepatol. 2013;11(1):38–42.PubMedCrossRef

Title: Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective
Authors: Angel Lanas
Carla J. Gargallo
Publication date: 01-06-2015
Publisher: Springer Japan
Published in: Journal of Gastroenterology / Issue 6/2015
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI: https://doi.org/10.1007/s00535-015-1038-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2015

Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial

Overexpression of NRG1 promotes progression of gastric cancer by regulating the self-renewal of cancer stem cells

Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA

Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients

Erratum to: Liver stiffness measurement by acoustic radiation force impulse is useful in predicting the presence of esophageal varices or high-risk esophageal varices among patients with HCV-related cirrhosis

Pancreatic congestion in liver cirrhosis correlates with impaired insulin secretion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page